Therapeutic options in neuromyelitis optica spectrum disorders

References

• Lennon V, Wingerchuk D, Kryzer T, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–2112.
   PubMed Web of Science ®Google Scholar
• Lennon V, Kryzer T, Pittock S, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–477.
   PubMed Web of Science ®Google Scholar
• Wingerchuk D, Hogancamp W, O’Brien P, et al. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53:1107–1114.
   PubMed Web of Science ®Google Scholar
• Wingerchuk D, Lennon V, Pittock S, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–1489.
   PubMed Web of Science ®Google Scholar
• Wingerchuk D, Banwell B, Bennett J, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130:1235–1243.
   PubMed Web of Science ®Google Scholar
• Waters P, Jarius S, Littleton E, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol. 2008;65:913–919.
   PubMedGoogle Scholar
• Waters P, McKeon A, Leite MI, et al. Serological diagnosis of NMO: a multicentre comparison of aquaporin-4-IgG assays. Neurology. 2012;78:665–671.
   PubMed Web of Science ®Google Scholar
• Wingerchuk D, Lennon V, Lucchinetti C, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805–815.
   PubMed Web of Science ®Google Scholar
• Juryńczyk M, Weinshenker B, Akman-Demir G, et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol. 2016;263(1):140–149. doi:10.1007/s00415-015-7952-8
   Web of Science ®Google Scholar
• Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies. JAMA Neurol. 2014;71:276–283.
   PubMed Web of Science ®Google Scholar
• Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474–481.
   PubMed Web of Science ®Google Scholar
• Kitley J, Leite MI, Küker W, et al. Longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies. JAMA Neurol. 2013;70:1375–1381.
   PubMed Web of Science ®Google Scholar
• Piccolo L, Woodhall M, Tackley G, et al. Isolated new onset ‘atypical’ optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. J Neurol. 2016;263(2):370-379. doi:10.1007/s00415-015-7983-1
   PubMedGoogle Scholar
• Kitley J, Leite I, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135:1834–1849.
   PubMed Web of Science ®Google Scholar
• Collongues N, Cabre P, Marignier R, et al. A benign form of neuromyelitis optica. Does it exist? Arch Neurol. 2011;68:918–924.
   PubMedGoogle Scholar
• Palace J, Leite MI, Leite I, et al. A practical guide to the treatment of neuromyelitis optica. Pract Neurol. 2012;12:209–214.
   PubMedGoogle Scholar
• Weinshenker B, O’Brien P, Petterson T, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878–886.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007;13:128–132.
   PubMed Web of Science ®Google Scholar
• Bonnan M, Valentino R, Olindo S, et al. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler. 2009;15:487–492.
   PubMed Web of Science ®Google Scholar
• Magana S, Keegan B, Weinshenker B, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol. 2011;68:870–878.
   PubMed Web of Science ®Google Scholar
• Wang K, Wang S, Lee C, et al. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci. 2011;18:43–46.
   PubMed Web of Science ®Google Scholar
• Bonnan M, Cabre P. Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int. 2012;2012:787630. doi:10.1155/2012/787630
   PubMedGoogle Scholar
• Lim Y, Pyun S, Kang B, et al. Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler. 2013;19:1216–1218.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim W, Huh S, et al. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol. 2013;9:36–42.
   PubMed Web of Science ®Google Scholar
• Merle H, Olindo S, Jeannin S, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol. 2012;130:858–862.
   PubMedGoogle Scholar
• Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014;20:501–504.
   PubMed Web of Science ®Google Scholar
• Grossman J, Gordon R, Ranganath V, et al. American college of rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62:1515–1526.
   PubMed Web of Science ®Google Scholar
• Greenberg B. Placebo studies should not be undertaken in NMO-No. Mult Scler. 2015;21:691–693.
   PubMed Web of Science ®Google Scholar
• Tackley G, O’Brien F, Rocha J, et al. Neuromyelitis optica relapses: Race and rate, immunosuppression and Impairment. Multiple Sclerosis and Related Disorders. Forthcoming 2016.
   Google Scholar
• Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007;13:968–974.
   PubMed Web of Science ®Google Scholar
• Norwood F, Dhanjal M, Hill M, et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. J Neurol Neurosurg Psychiatry. 2014;85(5):538–543.
   PubMed Web of Science ®Google Scholar
• Sammaritano L, Bermas B. Rheumatoid arthritis medications and lactation. Curr Opin Rheumatol. 2014;26:354–360.
   PubMed Web of Science ®Google Scholar
• Costanzi C, Matiello M, Lucchinetti C, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77:659–666.
   PubMed Web of Science ®Google Scholar
• Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler. 2014;20:1533–1540.
   PubMed Web of Science ®Google Scholar
• Qiu W, Kermode A, L R, et al. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci. 2015;22:1178–1182.
   PubMed Web of Science ®Google Scholar
• Mandler R, Ahmed W, Dencoff J. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51:1219–1220.
   PubMed Web of Science ®Google Scholar
• Bichuetti D, Lobato De Oliveira E, Oliveira D, et al. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol. 2010;67:1131–1136.
   PubMedGoogle Scholar
• Mealy M, Wingerchuk D, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71:324–330.
   PubMed Web of Science ®Google Scholar
• Higgs J, Payne K, Roberts C, et al. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics. 2010;11:177–188.
   PubMed Web of Science ®Google Scholar
• Jacob A, Matiello M, Weinshenker B, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66:1128–1133.
   PubMedGoogle Scholar
• Huh S, Kim Shyun S-H, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71:1372–1378.
   PubMed Web of Science ®Google Scholar
• Gerosa M, Meroni P, Cimaz R. Safety considerations when prescribing immunosuppression medication to pregnant women. Expert Opin Drug Saf. 2014;13:1591–1599.
   PubMed Web of Science ®Google Scholar
• Jacob A, Weinshenker B, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65:1443–1448.
   PubMed Web of Science ®Google Scholar
• Bedi G, Brown A, Delgado S, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17:1225–1230.
   PubMed Web of Science ®Google Scholar
• Pellkofer H, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76:1310–1315.
   PubMed Web of Science ®Google Scholar
• Kim S, Huh S, Lee S, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70:1110–1117.
   PubMed Web of Science ®Google Scholar
• Kim S, Jeong I, Hyun J, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of fcgr3a polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72:989–995.
   PubMed Web of Science ®Google Scholar
• Zephir H, Bernard-Valnet R, Lebrun C, et al. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol. 2015;262:2329–2335.
   PubMed Web of Science ®Google Scholar
• Collongues N, Brassat D, Maillart E, et al. Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler. 2015. pii: 1352458515602337. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Greenberg B, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler. 2012;18:1022–1026.
   PubMed Web of Science ®Google Scholar
• Perumal J, Kister I, Howard J, et al. Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2:e61.
   PubMed Web of Science ®Google Scholar
• Zaheer F, Berger J. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf. 2012;3:227–239.
   PubMedGoogle Scholar
• Chakravarty E, Murray E, Kelman A, et al. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499–1506.
   PubMed Web of Science ®Google Scholar
• Kim W, Kim S, Nakashima I, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology. 2012;78:1264–1267.
   PubMed Web of Science ®Google Scholar
• Jeong I, Park B, Kim S, et al. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler. 2015 Jun 3. pii: 1352458515587752. [ Epub ahead of print].
   Google Scholar
• Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013;84:918–921.
   PubMed Web of Science ®Google Scholar
• Ramanathan R, Malhotra K, Scott T. Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol. 2014;14:51.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol. 2006;63:957–963.
   PubMedGoogle Scholar
• Kim S, Kim W, Park M, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol. 2011;68:473–479.
   PubMedGoogle Scholar
• Cabre P, Olindo S, Marignier R, et al. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry. 2013;84:51–516.
   Google Scholar
• Meyts I, Jansen K, Renard M. Neuromyelitis optica-IgG+ optic neuritis associated with celiac disease and dysgammaglobulinemia: a role for tacrolimus? Eur J Paed Neurol. 2011;15:265–267.
   PubMed Web of Science ®Google Scholar
• Zheng X, Zhang X, Liu X, et al. Patient with neuromyelitis optica spectrum disorder combined with Sjögren’s syndrome relapse free following tacrolimus treatment. Intern Med. 2014;53:2377–2380.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Kinoshita M, Tanaka K. Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders. Mult Scler J. 2015;21:669.
   PubMed Web of Science ®Google Scholar
• Mok C, To C, Mak A, et al. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol. 2008;35:172–174.
   PubMed Web of Science ®Google Scholar
• Yaguchi H, Sakushima K, Takahashi I, et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med. 2013;52:969–972.
   PubMed Web of Science ®Google Scholar
• Lee D, Laemmer A, Waschbisch A, et al. Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report. J Med Case Rep. 2014;8:155.
   PubMedGoogle Scholar
• Kageyama T, Komori M, Miyamoto K, et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol. 2013;260:627–634.
   PubMed Web of Science ®Google Scholar
• Magraner M, Coret F, Casanova B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurología. 2013;28:65–72.
   PubMed Web of Science ®Google Scholar
• Viswanathan S, Wong A, Quek A, et al. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. J Neuroimmunol. 2015;282:92–96.
   PubMed Web of Science ®Google Scholar
• Khatri B, Kramer J, Dukic M, et al. Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica. J Clin Apheresis. 2012;27:183–192.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Yokoyama K, Misu T, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol. 2008;255:305–307.
   PubMed Web of Science ®Google Scholar
• Palace J, Leite MI, Nairne A, et al. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010;67:1016–1017.
   PubMedGoogle Scholar
• Shimizu J, Hatanaka Y, Hasegawa M, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010;75:1423–1427.
   PubMed Web of Science ®Google Scholar
• Qian P, Cross A, Naismith R. Lack of response to monoclonal antibody therapy in neuromyelitis optica. Arch Neurol. 2011;68:1207–1209.
   PubMedGoogle Scholar
• Barnett M, Prineas J, Buckland M, et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012;18:108–112.
   PubMed Web of Science ®Google Scholar
• Jacob A, Hutchinson M, Elsone L, et al. Does natalizumab therapy worsen neuromyelitis optica? Neurology. 2012;79:1065–1066.
   PubMed Web of Science ®Google Scholar
• Min J, Kim B, Lee K. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012;18:113–115.
   PubMed Web of Science ®Google Scholar
• Gelfand J, Cotter J, Klingman J, et al. Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurol Neuroimmunol Neuroinflammation. 2014;1:e34.
   PubMedGoogle Scholar
• Bergamaschi R, Uggetti C, Tonietti S, et al. A case of relapsing neuromyelitis optica treated with glatiramer acetate. J Neurol. 2003;250:359–361.
   PubMed Web of Science ®Google Scholar
• Gartzen K, Limmroth V, Putzki N. Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. Eur J Neurol. 2007;14:e12–3.
   PubMedGoogle Scholar
• Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81:1197–1204.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
   PubMed Web of Science ®Google Scholar
• Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity dependent entity. Neurology. 2013;80:2194–2200.
   PubMed Web of Science ®Google Scholar
• Cobo-Calvo A, et al. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications. Mult Scler. 2015;pii:1352458515591071. Epub ahead of print.
   Google Scholar
• Hoftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015;21:866–874.
   PubMed Web of Science ®Google Scholar
• Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA. 2011;108:4701–3706.
   Google Scholar
• Icoz S, Tuzun E, Kurtuncu M, et al. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci. 2010;120:71–75.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Sato Y, et al. CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. J Neurol Neurosurg Psychiatry. 2012;83:339–340.
   PubMed Web of Science ®Google Scholar
• Ayzenberg I, Kleiter I, Schroder I, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013;70:394–397.
   PubMed Web of Science ®Google Scholar
• Kieseier B, Stüve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol. 2013 March 1;70(3):390–393.
   PubMed Web of Science ®Google Scholar
• Lauenstein A, Stettner M, Keiseier B, et al. Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab. BMJ Case Reports. 2014 Mar 26;2014. pii: bcr2013202939. doi:10.1136/bcr-2013-202939
   PubMedGoogle Scholar
• Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72:756–763.
   PubMed Web of Science ®Google Scholar
• Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study. Neurology. 2014;82:1302–1306.
   PubMed Web of Science ®Google Scholar
• Kuroda H, Fujihara K, Takano R, et al., et al. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol. 2013;254:178–182.
   PubMed Web of Science ®Google Scholar
• Nytrova P, Potlukova E, Kemlink D, et al. Complement activation in patients with neuromyelitis optica. J Neuroimmunol. 2014;274:185–191.
   PubMed Web of Science ®Google Scholar
• Pittock S, Lennon V, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12:554–562.
   PubMed Web of Science ®Google Scholar
• Levy M, Mealy M. Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neuroinflammation. 2014;1:e5.
   PubMedGoogle Scholar
• Tradtrantip L, Asavapanumas N, Phuan P, et al. Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model. PLoSone. 2014;9:e106824.
   PubMed Web of Science ®Google Scholar
• Mastellos D, Yancopoulou D, Kokkinos P, et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest. 2015;45:423–440.
   PubMed Web of Science ®Google Scholar
• Lucchinetti C, Mandler R, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;125:1450–1461.
   PubMed Web of Science ®Google Scholar
• Roemer S, Parisi J, Lennon V, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130:1194–1205.
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Zhang H, Saadoun S, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol. 2012;71:314–322.
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Ratelade J, Zhang H, et al. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol. 2013;73:77–85.
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Asavapanumas N, Verkman A. Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol Pharmacol. 2013;83:1268–1275.
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Zhang H, Anderson M, et al Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. Faseb J. 2012;26:2197–2208.
   PubMed Web of Science ®Google Scholar